Findings

What do systematic reviews say?

4 questions · 4 findings · 4 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 25%Low 2 · 50%Moderate 1 · 25%High 0 · 0%

Adverse events with anti‐gram‐positive antibiotics vs placebo

Overall mortality · people with cancer who have febrile neutropenia

Mortality with anti‐gram‐positive antibiotics showed no clear difference in overall mortality compared with placebo (moderate certainty).

1 finding from 1 review

Empirical antibiotics targeting gram‐positive bacteria for the treatment of febrile neutropenic patients with cancer 2017 · Cochrane Headline outcomes only
RR 0.9 [0.64, 1.25]
8 studies · 1242 participants
Moderate

Intervention not reported

Overall mortality · treating infections in people with neutropenia or neutrophil dysfunction

It is very uncertain whether the intervention changes overall mortality (very low certainty).

1 finding from 1 review

Granulocyte transfusions for treating infections in people with neutropenia or neutrophil dysfunction 2016 · Cochrane Headline outcomes only
RR 0.75 [0.54, 1.04]
6 studies · 321 participants
Very low

Benefits and harms of CSF plus antibiotics vs antibiotics alone

Overall mortality · people with chemotherapy‐induced febrile neutropenia

Benefits and harms of CSF plus antibiotics showed no clear difference in overall mortality compared with antibiotics alone (low certainty).

1 finding from 1 review

Colony‐stimulating factors for chemotherapy‐induced febrile neutropenia 2014 · Cochrane Headline outcomes only
HR 0.74 [0.47, 1.16]
13 studies · 1335 participants
Low

Dexrazoxane vs no cardioprotective intervention

Has died · children with cancer receiving anthracyclines

Dexrazoxane showed no clear difference in overall mortality (Reported as number of participants who died) compared with no cardioprotective intervention (low certainty).

1 finding from 1 review

Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines 2022 · Cochrane Headline outcomes only
HR 1.01 [0.72, 1.42]
3 studies · 1008 participants
Low